Chronic lymphocytic leukaemia     

FOI REFERENCE: 24466   FOI DATE: 23^rd October 2024     

How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

Answer:  31 Patients

How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

Answer:  Unknown

Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

FCR (fludarabine + cyclophosphamide + rituximab) 0 Patients

FR (fludarabine + rituximab)   0  Patients

BR (bendamustine + rituximab)  0 Patients

Bendamustine monotherapy   0 Patients

RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)  0 Patients

Obinutuzumab ± chlorambucil  0 Patients

Rituximab + chlorambucil  0 Patients

Ofatumumab 0 Patients

Other – please specify

ALCALABRUTINIB  20  Patients

RITUXIMAB SINGLE   5 Patients